Health Condition 1: K319- Disease of stomach and duodenum, unspecified
Conditions
Interventions
Intervention1: Injection Sugammadex
: injection Sugammadex 2mg/kg will be given Intravenously & time duration for reversal of neuromuscular blockage will be recorded
Control Intervention1: Injection
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: Patients under ASA grade I, II. Patients scheduled for surgeries to be performed under general anaesthesia. Patients willing to sign written informed consent
Exclusion criteria
Exclusion criteria: Patients with ASA Grade III & IV. Patients with known allergy any of the study drugs. Patients receiving Neuromuscular blocking agents other than Inj. Vecuronium
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to achieve adequate neuromuscular recovery.Timepoint: Time from study drug administration (at the appearance of second twitch i.e T2 after last dose of vecuronium) to tracheal extubation (TOFR = 0.9) | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of residual neuromuscular blockade (RNMB)Timepoint: At extubation and on arrival in post op recovery room;Time to orientationTimepoint: At 5, 10, 15 min post-reversal | — |
Countries
India
Contacts
Public ContactDr Tejas Pangale
Parul Institute of Medical Sciences and Research
Outcome results
None listed